ERTUGLIFLOZIN

Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion through urine.

Indications

-Type 2 Diabetes Mellitus (as monotherapy or in combination with other antidiabetic agents) -May be used to reduce cardiovascular risks in diabetic patients with established heart disease

Dosage

-Initial Dose: 5 mg once daily, taken in the morning with or without food -Maintenance Dose: Can be increased to 15 mg once daily based on individual response and tolerability -Dose adjustment may be required in patients with renal impairment

Contra-Indications

-Hypersensitivity to Ertugliflozin or any of its components -Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) -Type 1 Diabetes Mellitus and diabetic ketoacidosis -Severe hepatic impairment

Special Precautions

-Monitor kidney function before and during treatment -Increased risk of ketoacidosis, especially in cases of prolonged fasting, excessive alcohol consumption, or low carbohydrate intake -May increase the risk of urinary tract infections and genital mycotic infections -Use with caution in elderly patients and those with dehydration risk

Side Effects

-Urinary tract infections -Genital fungal infections -Increased urination -Hypotension -Ketoacidosis (rare but serious) -Elevated cholesterol levels

Drug Interactions

-Diuretics: May enhance the risk of dehydration and hypotension -Insulin & Insulin Secretagogues: May increase the risk of hypoglycemia -NSAIDs & ACE Inhibitors: May impact renal function -Rifampin & Other Inducers: May reduce the efficacy of Ertugliflozin